What is Incyte Corporation's share price today?
Incyte Corporation (INCY) share price today is $122.91 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $123.34 and a day low of $118.11.What exchange does Incyte Corporation stock trade on, and under what ticker symbol?
Incyte Corporation stock trades on NASDAQ under the ticker symbol INCY.What is Incyte Corporation's market capitalization?
Incyte Corporation's market capitalization is $24.46B as of November 5, 2026 at 2:29 AM IST.What is Incyte Corporation's price-to-earnings (P/E) ratio?
Incyte Corporation's price-to-earnings (P/E) ratio is 61.24 as of November 4, 2026.What is Incyte Corporation's price-to-book (P/B) ratio?
Incyte Corporation's price-to-book (P/B) ratio is 4.34 as of November 4, 2026.Can Indian investors buy Incyte Corporation shares?
Yes, You can buy Incyte Corporation shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Incyte Corporation shares from India?
Indian investors can buy Incyte Corporation shares in three steps: 1. Search Incyte Corporation on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Incyte Corporation shares for Indian investors?
Since Incyte Corporation trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Incyte Corporation shares via Tickertape?
Indian investors can start investing in Incyte Corporation (INCY) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0813 shares at the current price of $122.91.
$
₹
$122.914.52% (+5.32)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
61.24
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
4.34
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$1.96
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
10.82
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
6.71%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 28 analysts reports
Buy12 analysts
Hold15 analysts
Sell1 analyst
Price Upside
+11.47%
Earnings Growth
-49.11%
Rev. Growth
+17.35%
Company Profile
Company Profile
ABBV
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$117.59Baseline
Analyst Target - 1 year
Target$131.08+11.47%
All values in $
2026
Current$117.59Baseline
Analyst Target - 1 year
Target$131.08+11.47%
All values in $
Revenue Forecast
Revenue Forecast
Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 17.35% growth, versus a trailing 3-year CAGR of 14.84%.
2025
Current$5.14Baseline
Forecast for Dec 2026
High$6.11+18.92%
Average$6.03+17.35%
Low$5.90+14.91%
All values in $ Billion
2025
Current$5.14Baseline
Forecast for Dec 2026
High$6.11+18.92%
Average$6.03+17.35%
Low$5.90+14.91%
All values in $ Billion
Earnings Per Share Forecast
Earnings Per Share Forecast
Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies -49.11% growth, versus a trailing 3-year CAGR of 34.67%.
2025
Current$6.79Baseline
Forecast for Dec 2026
High$4.38-35.49%
Average$3.46-49.11%
Low$2.76-59.35%
All values in $
2025
Current$6.79Baseline
Forecast for Dec 2026
High$4.38-35.49%
Average$3.46-49.11%
Low$2.76-59.35%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
| Financial Year | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.04 | 1.13 | 1.17 | 1.05 | 1.21 | 1.36 | 1.50 | 1.27 | 1.67 | 1.55 |
Gross Profit | 0.96 | 1.05 | 1.09 | 0.97 | 1.13 | 1.26 | 1.38 | 1.16 | 1.56 | 1.44 |
| Net Income | -0.44 | 0.10 | 0.20 | 0.15 | 0.40 | 0.42 | 0.29 | 0.30 | 0.58 | -0.78 |
| Net Profit Margin | -42.59% | 9.35% | 17.07% | 15.02% | 33.31% | 31.05% | 19.86% | 23.83% | 34.98% | -50.39% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Incyte Corporation | 61.24 | 4.34 | 10.82 |
| AbbVie Inc | 50.67 | 50.45 | 0.60 |
| Amgen Inc | 28.90 | 21.55 | 2.77 |
Price Comparison
Price Comparison
Compare INCY with any stock or ETFCompare INCY with any stock or ETF
Comparing from
INCY
ABBV
AMGN
The 12-month consensus target implies 11.47% growth, versus a trailing 3-year CAGR of 28.94%.